Watch out Claritin: Aldeyra announces clean sweep in PhIII for new allergy drug

Aldeyra Therapeutics’ stock $ALDX is surging after they posted sweeping results in a Phase III trial for their lead therapy.

Aldeyra announced Tuesday that the molecule, known as reproxalap, reduced the number of times patients with a form of seasonal allergies scratched their eyes after being exposed to ragweed pollen. It also successfully reduced tearing, redness around the eyes, and patient’s score on a scale that measures how severe their reaction was overall.